NVO

Novo Nordisk

Exchange: NYSESector: HealthcareIndustry: Biotechnology

Values in USD · ADR · Reports in DKK

Novo Nordisk is a leading global health care company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Current Price

—

GoodMoat Value

$87.03

Profile

Valuation (TTM)

Market Cap—

P/E—

EV—

P/B—

Shares Out—

P/Sales—

Revenue—

EV/EBITDA—

Novo Nordisk (NVO) Financial Statements

Values in USD · ADR · Reports in DKK

NVO Financial Data

EBITDA—

Revenue (TTM)—

Gross Profit (TTM)—

Gross Margin—

Operating Margin—

ROE—

ROA—

Debt/Equity—

Current Ratio—

FCF—

FCF Yield—

Piotroski F-Score—

Rev/Share (TTM)—

50-Day MA—

200-Day MA—

Shares Outstanding—

NVO Computed Insights

FCF—

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

NVO Financial Statements & Data

Novo Nordisk (NVO) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Novo Nordisk's financial performance and position as a Healthcare company.

Weighted average cost of capital (WACC) is 10.00%.

GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Novo Nordisk's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.